The global peri-implantitis treatment market is anticipated to be valued at US$ 2.3 Billion in 2022, forecast to grow at a CAGR of 8.7% to be valued at US$ 4.5 Billion from 2022 to 2032. Growth is attributed to the rising usage of dental implants for prosthetic rehabilitation. From 2021 to 2022, a Y-o-Y growth rate of 4.5% is expected for the market, inclining from its previous valuation of US$ 2.2 Billion in 2021.
| Report Attribute | Details |
|---|---|
| Estimated Base Year Value (2021) | US$ 2.2 Billion |
| Expected Market Value (2022) | US$ 2.3 Billion |
| Anticipated Forecast Value (2032) | US$ 4.5 Billion |
| Projected Growth Rate (2022 to 2032) | 8.7% CAGR |
Dental implants have turned into an established therapy in dentistry essential to replace missing teeth in different clinical situations. Peri-implantitis is a site-specific infectious disease, that affects the soft and hard tissue surrounding a dental implant. Peri-Implantitis is an inflammatory reaction with the loss of a supporting bone in the tissues surrounding a dental implant.
According to the National Center for Biotechnology Information (NCBI), over an average follow-up of 2 years in the USA, the prevalence of peri-implantitis was 34.0% on the patient level and 21% on the implant level. The rising demand for dental implants is a major factor that contributes to the growth of the market for peri-implantitis. However, the lack of awareness regarding the treatment is a major factor that hampers the market growth during the forecast period. People having a history of periodontal disease are more susceptible to peri-implantitis.
According to the Centers for Disease Control and Prevention (CDC), in 2019, 47.2% of adults aged 30 years in the USA had some form of periodontal disease, with the condition being more common in men than women, as they are more prone to smoking and health conditions like diabetes.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The rising usage of dental implants for prosthetic rehabilitation is one of the major factors that is expected to accelerate the global peri-implantitis market during the forecast period. Growing public knowledge about oral hygiene has resulted in an increase in dental visits, which in turn is likely to boost the demand for the peri-implantitis treatment market.
Moreover, the aging population is likely to play a significant role in fueling the demand for peri-implantitis treatment over the analysis period. Technological advancements have resulted in several dental methods such as dental grafting, which are expected to present lucrative opportunities for market players in the peri-implantitis market.
Increased tobacco use and smoking rates cause a variety of oral disorders, which are expected to further increase the growth for peri-implantitis treatment during the forecast period.
Additionally, the rising demand for anti-aging treatments and procedures such as wrinkles, age spots, and other procedures is expected to propel the market growth during the forecast period, owing to the growing elderly population. Furthermore, advanced microdermabrasion devices are likely to expand in popularity among consumers, which would boost market expansion over the analysis period.
The high cost of dental implants is one of the major factors that is expected to impede the growth of the peri-implantitis treatment market during the forecast period. In addition, a lack of skilled dental specialties can restrain the peri-implantitis treatment market.
In addition, the other major setback for the market’s growth is that bone loss is only apparent in radiographs when 30% of the bone mass is lost, which can make early detection difficult. This in turn is expected to restrain market growth.
Moreover, lack of awareness regarding the treatment is a major factor that hampers the peri-implantitis market in developing countries.
Principal Consultant
The peri-implantitis market in North America is expected to hold the largest share of US$ 719 Million, attributed to the availability of high healthcare expenditure. The regional market is expected to reach a CAGR of 8.3% during the forecast period.
Factors such as the growing burden of dental diseases and well-developed healthcare facilities in the region are also expected to augment the market’s growth over the analysis period.
Additionally, the market in the region is expected to propel, owing to the rise in the geriatric population, increasing initiatives by the market players for technological advancements in peri-implantitis devices, and a highly aware population in the region.
The Asia-Pacific is expected to register the fastest growth in revenue generation for the peri-implantitis treatment market due to the large population in countries such as China, and India.
On the other hand, factors such as the rising number of market players focusing on the launch of dental equipment in the region are expected to accelerate market growth.
The availability of developed healthcare facilities and favorable government initiatives in India, China, and Japan are the other major factors that will boost the market growth in the Asia-Pacific region, over the forecast period.
Populous countries like India and China suffer from a heavy burden of oral diseases and Dental Implants (DIs) are prescribed widely by dental practitioners to replace lost natural teeth and are gaining prominence. Moreover, India and China are currently the largest tobacco-producing and consuming countries having the lowest smoking awareness. These are the factors that are expected to fuel the market for peri-implantitis in the region. The Asia-Pacific peri-implantitis market is expected to reach a CAGR of 8.1%.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the key participants present in the global Peri-implantitis Treatment market include Pfizer Inc., Cadila Pharmaceuticals, R.N. Laboratories Pvt. Ltd., Basic Pharma Life Science Pvt. Ltd., Prachi Pharmaceuticals Private Limited., Healthy Life Pharma Private Limited, Triveni chemicals, Geistlich Pharma, and Dawood & Tanner, among others.
Attributed to the presence of such a high number of participants, the market is highly competitive. While global players such as Pfizer Inc., Cadila Pharmaceuticals, and R.N. Laboratories Pvt. Ltd. account for a considerable market size, several regional-level players are also operating across key growth regions, particularly in the Asia Pacific.
Recent Developments:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 7% from 2022 to 2032 |
| Market Value in 2022 | US$ 2.3 Billion |
| Market Value in 2032 | US$ 4.5 Billion |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regional Scope |
|
| Country Scope |
|
| Key Companies Profiled |
|
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. |
FMI projects the global Peri-implantitis Treatment market to expand at a 7% value CAGR by 2032
Asia Pacific is expected to be the most opportunistic Peri-implantitis Treatment market, expanding at 8.1% CAGR
Pfizer Inc., Cadila Pharmaceuticals, R.N. Laboratories Pvt. Ltd., and Basic Pharma Life Science Pvt. Ltd. are some prominent Peri-implantitis Treatment manufacturers
1. Executive Summary | Peri-implantitis Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Method Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Method Type, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Method Type, 2022 to 2032 5.3.1. Surgical Treatment 5.3.1.1. Mechanical Debridement 5.3.1.2. Laser Debridement 5.3.1.3. Open Flap Debridement 5.3.1.4. Open Flap Debridement with guided bone generation 5.3.2. Non-Surgical Treatment 5.3.2.1. Surface Debridement 5.3.2.2. Antibiotics ( Chlorhexidine Digluconate ) 5.3.2.3. Others 5.4. Y-o-Y Growth Trend Analysis By Method Type, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Method Type, 2022 to 2032 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2022 to 2032 6.3.1. Hospitals 6.3.2. Dental Clinics 6.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By End User, 2022 to 2032 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. Asia Pacific 7.3.5. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Method Type 8.2.3. By End User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Method Type 8.3.3. By End User 8.4. Key Takeaways 9. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Method Type 9.2.3. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Method Type 9.3.3. By End User 9.4. Key Takeaways 10. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Method Type 10.2.3. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Method Type 10.3.3. By End User 10.4. Key Takeaways 11. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. China 11.2.1.2. Japan 11.2.1.3. South Korea 11.2.1.4. Malaysia 11.2.1.5. Singapore 11.2.1.6. Australia 11.2.1.7. Rest of Asia Pacific 11.2.2. By Method Type 11.2.3. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Method Type 11.3.3. By End User 11.4. Key Takeaways 12. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. GCC Countries 12.2.1.2. South Africa 12.2.1.3. Israel 12.2.1.4. Rest of Middle East and Africa 12.2.2. By Method Type 12.2.3. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Method Type 12.3.3. By End User 12.4. Key Takeaways 13. Key Countries Market Analysis 13.1. USA 13.1.1. Pricing Analysis 13.1.2. Market Share Analysis, 2021 13.1.2.1. By Method Type 13.1.2.2. By End User 13.2. Canada 13.2.1. Pricing Analysis 13.2.2. Market Share Analysis, 2021 13.2.2.1. By Method Type 13.2.2.2. By End User 13.3. Brazil 13.3.1. Pricing Analysis 13.3.2. Market Share Analysis, 2021 13.3.2.1. By Method Type 13.3.2.2. By End User 13.4. Mexico 13.4.1. Pricing Analysis 13.4.2. Market Share Analysis, 2021 13.4.2.1. By Method Type 13.4.2.2. By End User 13.5. Rest of Latin America 13.5.1. Pricing Analysis 13.5.2. Market Share Analysis, 2021 13.5.2.1. By Method Type 13.5.2.2. By End User 13.6. Germany 13.6.1. Pricing Analysis 13.6.2. Market Share Analysis, 2021 13.6.2.1. By Method Type 13.6.2.2. By End User 13.7. United Kingdom 13.7.1. Pricing Analysis 13.7.2. Market Share Analysis, 2021 13.7.2.1. By Method Type 13.7.2.2. By End User 13.8. France 13.8.1. Pricing Analysis 13.8.2. Market Share Analysis, 2021 13.8.2.1. By Method Type 13.8.2.2. By End User 13.9. Spain 13.9.1. Pricing Analysis 13.9.2. Market Share Analysis, 2021 13.9.2.1. By Method Type 13.9.2.2. By End User 13.10. Italy 13.10.1. Pricing Analysis 13.10.2. Market Share Analysis, 2021 13.10.2.1. By Method Type 13.10.2.2. By End User 13.11. Rest of Europe 13.11.1. Pricing Analysis 13.11.2. Market Share Analysis, 2021 13.11.2.1. By Method Type 13.11.2.2. By End User 13.12. China 13.12.1. Pricing Analysis 13.12.2. Market Share Analysis, 2021 13.12.2.1. By Method Type 13.12.2.2. By End User 13.13. Japan 13.13.1. Pricing Analysis 13.13.2. Market Share Analysis, 2021 13.13.2.1. By Method Type 13.13.2.2. By End User 13.14. South Korea 13.14.1. Pricing Analysis 13.14.2. Market Share Analysis, 2021 13.14.2.1. By Method Type 13.14.2.2. By End User 13.15. Malaysia 13.15.1. Pricing Analysis 13.15.2. Market Share Analysis, 2021 13.15.2.1. By Method Type 13.15.2.2. By End User 13.16. Singapore 13.16.1. Pricing Analysis 13.16.2. Market Share Analysis, 2021 13.16.2.1. By Method Type 13.16.2.2. By End User 13.17. Australia 13.17.1. Pricing Analysis 13.17.2. Market Share Analysis, 2021 13.17.2.1. By Method Type 13.17.2.2. By End User 13.18. Rest of Asia Pacific 13.18.1. Pricing Analysis 13.18.2. Market Share Analysis, 2021 13.18.2.1. By Method Type 13.18.2.2. By End User 13.19. GCC Countries 13.19.1. Pricing Analysis 13.19.2. Market Share Analysis, 2021 13.19.2.1. By Method Type 13.19.2.2. By End User 13.20. South Africa 13.20.1. Pricing Analysis 13.20.2. Market Share Analysis, 2021 13.20.2.1. By Method Type 13.20.2.2. By End User 13.21. Israel 13.21.1. Pricing Analysis 13.21.2. Market Share Analysis, 2021 13.21.2.1. By Method Type 13.21.2.2. By End User 13.22. Rest of the Middle East and Africa 13.22.1. Pricing Analysis 13.22.2. Market Share Analysis, 2021 13.22.2.1. By Method Type 13.22.2.2. By End User 14. Market Structure Analysis 14.1. Competition Dashboard 14.2. Competition Benchmarking 14.3. Market Share Analysis of Top Players 14.3.1. By Regional 14.3.2. By Method Type 14.3.3. By End User 15. Competition Analysis 15.1. Competition Deep Dive 15.1.1. Pfizer Inc. 15.1.1.1. Overview 15.1.1.2. Product Portfolio 15.1.1.3. Profitability by Market Segments 15.1.1.4. Sales Footprint 15.1.1.5. Strategy Overview 15.1.1.5.1. Marketing Strategy 15.1.2. Cadila Pharmaceuticals 15.1.2.1. Overview 15.1.2.2. Product Portfolio 15.1.2.3. Profitability by Market Segments 15.1.2.4. Sales Footprint 15.1.2.5. Strategy Overview 15.1.2.5.1. Marketing Strategy 15.1.3. R.N. Laboratories Pvt. Ltd. 15.1.3.1. Overview 15.1.3.2. Product Portfolio 15.1.3.3. Profitability by Market Segments 15.1.3.4. Sales Footprint 15.1.3.5. Strategy Overview 15.1.3.5.1. Marketing Strategy 15.1.4. Basic Pharma Life Science Pvt. Ltd. 15.1.4.1. Overview 15.1.4.2. Product Portfolio 15.1.4.3. Profitability by Market Segments 15.1.4.4. Sales Footprint 15.1.4.5. Strategy Overview 15.1.4.5.1. Marketing Strategy 15.1.5. Prachi Pharmaceuticals Private Limited. 15.1.5.1. Overview 15.1.5.2. Product Portfolio 15.1.5.3. Profitability by Market Segments 15.1.5.4. Sales Footprint 15.1.5.5. Strategy Overview 15.1.5.5.1. Marketing Strategy 15.1.6. Healthy Life Pharma Private Limited 15.1.6.1. Overview 15.1.6.2. Product Portfolio 15.1.6.3. Profitability by Market Segments 15.1.6.4. Sales Footprint 15.1.6.5. Strategy Overview 15.1.6.5.1. Marketing Strategy 15.1.7. Triveni Chemicals 15.1.7.1. Overview 15.1.7.2. Product Portfolio 15.1.7.3. Profitability by Market Segments 15.1.7.4. Sales Footprint 15.1.7.5. Strategy Overview 15.1.7.5.1. Marketing Strategy 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Peri-implantitis Treatment Market
